BRPI0924058A2 - anticorpos contra inibidor da via de fator tecidual - Google Patents

anticorpos contra inibidor da via de fator tecidual

Info

Publication number
BRPI0924058A2
BRPI0924058A2 BRPI0924058A BRPI0924058A BRPI0924058A2 BR PI0924058 A2 BRPI0924058 A2 BR PI0924058A2 BR PI0924058 A BRPI0924058 A BR PI0924058A BR PI0924058 A BRPI0924058 A BR PI0924058A BR PI0924058 A2 BRPI0924058 A2 BR PI0924058A2
Authority
BR
Brazil
Prior art keywords
tissue factor
pathway inhibitor
antibodies against
factor pathway
against tissue
Prior art date
Application number
BRPI0924058A
Other languages
English (en)
Inventor
Olsen Krogh Berit
Lauritzen Brian
Binow Sorensen Brit
Hilden Ida
Breinholt Jens
Thorn Clausen Jes
Hvilsted Olsen Ole
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924058(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0924058A2 publication Critical patent/BRPI0924058A2/pt
Publication of BRPI0924058B1 publication Critical patent/BRPI0924058B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

anticorpos contra inibidor da via de fator tecidual a invenção relaciona-se a anticorpos que especificamente se ligam ao inibidor da via de fator tecidual (tfpi) e que reduzem o tempo de coagulação do sangue. tais anticorpos têm utilidade no tratamento de indivíduos com uma coagulopatia.
BRPI0924058-6A 2008-12-22 2009-12-18 Anticorpos monoclonais, seus usos, bem como composição farmacêutica BRPI0924058B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172520.2 2008-12-22
EP08172520 2008-12-22
PCT/EP2009/067598 WO2010072691A1 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor

Publications (2)

Publication Number Publication Date
BRPI0924058A2 true BRPI0924058A2 (pt) 2019-10-15
BRPI0924058B1 BRPI0924058B1 (pt) 2021-08-17

Family

ID=40639722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924058-6A BRPI0924058B1 (pt) 2008-12-22 2009-12-18 Anticorpos monoclonais, seus usos, bem como composição farmacêutica

Country Status (23)

Country Link
US (5) US8361469B2 (pt)
EP (3) EP2379600B2 (pt)
JP (2) JP5714505B2 (pt)
KR (2) KR101600308B1 (pt)
CN (1) CN102325795B (pt)
AU (1) AU2009331570C1 (pt)
BR (1) BRPI0924058B1 (pt)
CA (1) CA2745317C (pt)
DK (1) DK2379600T4 (pt)
ES (1) ES2458665T5 (pt)
FI (1) FIC20250014I1 (pt)
FR (2) FR24C1008I1 (pt)
HU (1) HUS2500017I1 (pt)
IL (1) IL213356A (pt)
MX (1) MX2011006501A (pt)
NL (1) NL301310I2 (pt)
NO (1) NO2025013I1 (pt)
PL (1) PL2379600T5 (pt)
PT (1) PT2379600E (pt)
RU (1) RU2562114C2 (pt)
TW (1) TWI476003B (pt)
WO (1) WO2010072691A1 (pt)
ZA (1) ZA201104599B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
PL2694544T3 (pl) * 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
US20160009817A1 (en) * 2013-03-15 2016-01-14 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
EP2970497B1 (en) * 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CA2921652A1 (en) 2013-08-21 2015-02-26 Manuel A. Riquelme Compositions and methods for targeting connexin hemichannels
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US10550196B2 (en) * 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
MY178445A (en) * 2015-02-25 2020-10-13 Mogam Inst Biomedical Res Novel antibody binding to tfpi and composition comprising the same
KR102438650B1 (ko) * 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI832600B (zh) * 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
JP7094722B2 (ja) * 2018-02-28 2022-07-04 キヤノン株式会社 画像読取装置及び画像形成装置
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CA3115607A1 (en) * 2018-10-11 2020-04-16 Pfizer Inc. Dosage regimen for tfpi antagonists
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
US20230035617A1 (en) * 2019-11-13 2023-02-02 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2022063913A1 (en) 2020-09-24 2022-03-31 Novo Nordisk A/S Pharmaceutical formulation of concizumab and method of production thereof
CN116136537A (zh) * 2021-11-16 2023-05-19 北京积水潭医院 组织因子途径抑制物抗凝活性的检测方法和试剂盒及其应用
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
EP0539975A1 (en) † 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JPH06153981A (ja) 1992-11-30 1994-06-03 Teijin Ltd Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
EP2289550A3 (en) * 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US7585842B2 (en) 2004-04-16 2009-09-08 The Reagents Of The University Of California Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) * 2004-05-06 2006-03-21 National Semiconductor Corporation Bootstrapped bias mixer with soft start POR
EP1869082B1 (en) † 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101792032B1 (ko) * 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
EP2379599B1 (en) * 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
US8965454B2 (en) 2009-03-04 2015-02-24 Andrew Llc Amplifier system for cell sites and other suitable applications
JP2013502218A (ja) 2009-08-18 2013-01-24 バクスター・インターナショナル・インコーポレイテッド 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PT3345615T (pt) * 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
US8598008B2 (en) † 2010-10-20 2013-12-03 Texas Instruments Incorporated Stacked ESD clamp with reduced variation in clamp voltage
WO2012109675A1 (en) † 2011-02-11 2012-08-16 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PL2694544T3 (pl) † 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
AU2013235567A1 (en) † 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
MY178445A (en) † 2015-02-25 2020-10-13 Mogam Inst Biomedical Res Novel antibody binding to tfpi and composition comprising the same
KR102438650B1 (ko) † 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도

Also Published As

Publication number Publication date
ES2458665T5 (es) 2021-06-30
US20130251721A1 (en) 2013-09-26
US20190211112A1 (en) 2019-07-11
PT2379600E (pt) 2014-04-29
JP2012513377A (ja) 2012-06-14
JP5714505B2 (ja) 2015-05-07
MX2011006501A (es) 2011-07-12
FR25C1014I2 (fr) 2026-03-27
KR20160031028A (ko) 2016-03-21
EP2746294A2 (en) 2014-06-25
EP2746294A3 (en) 2015-01-07
US8652471B2 (en) 2014-02-18
RU2011129068A (ru) 2013-01-27
TW201026330A (en) 2010-07-16
NO2025013I1 (no) 2025-02-25
FR24C1008I1 (fr) 2024-04-19
FIC20250014I1 (fi) 2025-03-17
US20130251722A1 (en) 2013-09-26
US20170114147A1 (en) 2017-04-27
ES2458665T9 (en) 2025-04-22
IL213356A0 (en) 2011-07-31
PL2379600T3 (pl) 2014-07-31
DK2379600T4 (da) 2021-01-04
KR20110103432A (ko) 2011-09-20
ES2458665T3 (es) 2014-05-06
EP2379600A1 (en) 2011-10-26
TWI476003B (zh) 2015-03-11
ZA201104599B (en) 2012-03-28
CA2745317C (en) 2019-03-05
EP3260466A1 (en) 2017-12-27
JP6114326B2 (ja) 2017-04-12
AU2009331570C1 (en) 2024-04-18
AU2009331570A1 (en) 2011-06-30
CN102325795B (zh) 2015-03-25
NL301310I2 (nl) 2025-02-11
HUS2500017I1 (hu) 2025-04-28
RU2562114C2 (ru) 2015-09-10
BRPI0924058B1 (pt) 2021-08-17
EP2379600B1 (en) 2014-01-22
AU2009331570B2 (en) 2013-10-17
PL2379600T5 (pl) 2021-03-08
JP2015178495A (ja) 2015-10-08
EP2379600B2 (en) 2020-10-14
KR101600308B1 (ko) 2016-03-07
US9574011B2 (en) 2017-02-21
WO2010072691A1 (en) 2010-07-01
US8361469B2 (en) 2013-01-29
IL213356A (en) 2017-06-29
DK2379600T3 (da) 2014-04-28
KR101745394B1 (ko) 2017-06-09
CN102325795A (zh) 2012-01-18
CA2745317A1 (en) 2010-07-01
US20110318356A1 (en) 2011-12-29
FR25C1014I1 (fr) 2025-06-20

Similar Documents

Publication Publication Date Title
BRPI0924058A2 (pt) anticorpos contra inibidor da via de fator tecidual
CY1122076T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
ECSP11011297A (es) Proteinas ligadoras il-17
TW200833330A (en) Substituted dihydropyrazolones and their use
PL2215480T3 (pl) Narzędzia do diagnostyki i terapii chorób zmieniających funkcję naczyń
PT2905030T (pt) Anticorpos humanos que ligam ao gene de ativação de linfócitos 3 (lag-3) e utilizações dos mesmos
AU2016204344A1 (en) Improved methods and compositions for wound healing
EP2118123A4 (en) STABILIZED P53 PEPTIDES AND ITS USES
TR201820051T4 (tr) Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
BRPI0815020A2 (pt) Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
WO2010071894A3 (en) Tfpi inhibitors and methods of use
TN2010000074A1 (en) Cyclic depsipeptides
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ
EA200970718A1 (ru) Лиганд-модифицированные полиоксогидроксидные материалы с ионами металла, их применение и способы их получения
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
ATE429477T1 (de) Acrylatklebemasse mit wasserfesten klebeigenschaften
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
ATE517642T1 (de) Kombination zum verkleben von biologischen geweben

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.